🏛️ Verified NIH Record • Updated 2026-06-04
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus (NCT06613360)
A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic Lupus Erythematosus (SLE)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Cullinan Therapeutics Inc.
🩺 Plain-English Summary (8th-Grade Level)
Phase 1b, open-label study of CLN-978 administered subcutaneously in patients with Moderate to Severe Systemic Lupus Erythematosus (SLE).
Who can join: Review the eligibility criteria below.
Location: AARA Clinical Research — Avondale, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- AARA Clinical Research — Avondale, Arizona
- AARA Clinical Research — Tucson, Arizona
- Omega Research Group — Orlando, Florida
- University of Iowa — Iowa City, Iowa
- Columbia University Medical Center — New York, New York
- University of Rochester Medical Center — Rochester, New York
- Regional One Health — Memphis, Tennessee
- Stryde Research — Plano, Texas
- Tranquil Clinical Research — Webster, Texas
- Intermountain Health — Salt Lake City, Utah
- Royal Melbourne Hospital — Parkville,
- Osteoporosis Solutions — Victoria Park,
- Multi profile Hospital for Active Treatment Sveta Sofia — Sofia,
- CHU de Nantes — Nantes,
- University Hospital Saint Etienne — Saint-Priest-en-Jarez,
- Centre Hospitalier Universitaire de Toulouse — Toulouse,
- ARENSIA Exploratory Medicine, LLC — Tbilisi,
- Timofei Moșneaga Republican Clinical Hospital — Chisinau,
- ARENSIA Exploratory Medicine S.R.L. — Bucharest,
- Arensia Exploratory Medicine — Cluj-Napoca,
📞 Contact the Study Coordinator
Phone: (617) 410-4650
Email: ClinOps@cullinantx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in SLE
- Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus — Anniston, Alabama
- Myocardial Inflammation in Systemic Lupus Erythematosus — Columbus, Ohio
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients — Charleston, South Carolina
- CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Philadelphia, Pennsylvania
Explore by condition: All SLE clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.